We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+8.97%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
-$24.8M
Cap. Flow
-$144M
Cap. Flow %
-5.21%
Top 10 Hldgs %
47.94%
Holding
172
New
14
Increased
31
Reduced
25
Closed
39

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$27.4M
2
SHPG
Shire pic
SHPG
+$25.4M
3
ILMN icon
Illumina
ILMN
+$22.1M
4
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
5
HCA icon
HCA Healthcare
HCA
+$14.3M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$72.3M
2
ALKS icon
Alkermes
ALKS
+$45.9M
3
AET
Aetna Inc
AET
+$36.3M
4
MDRX
Veradigm Inc. Common Stock
MDRX
+$23M
5
AKRX
Akorn Inc
AKRX
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 91.34%
2 Miscellaneous 4.98%
3 Real Estate 3.68%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
76
Karyopharm Therapeutics
KPTI
$37.9M
$6.63M 0.24%
33,355
-27,903
-46% -$6.04M
CLLS
77
Cellectis
CLLS
$140M
$6.43M 0.23%
207,250
+48,868
+31% +$1.48M
TVTX icon
78
Travere Therapeutics
TVTX
$5.96B
$6.37M 0.23%
+329,949
New +$6.59M
CYTO
79
DELISTED
Altamira Therapeutics Ltd
CYTO
$6.2M 0.22%
16
-10
-38% -$2.88M
HRTX icon
80
Heron Therapeutics
HRTX
$60.1M
$5.85M 0.21%
219,000
– –
AVDL
81
DELISTED
Avadel Pharmaceuticals
AVDL
$5.79M 0.21%
+474,288
New +$7.39M
EXEL icon
82
Exelixis
EXEL
$14.2B
$5.78M 0.21%
+1,023,877
New +$5.73M
SAGE
83
DELISTED
Sage Therapeutics
SAGE
$5.7M 0.21%
97,800
– –
AXDX
84
DELISTED
Accelerate Diagnostics
AXDX
$5.69M 0.21%
26,463
+12,000
+83% +$2.19M
ELGX
85
DELISTED
Endologix Inc
ELGX
$5.46M 0.2%
55,100
– –
AKRX
86
DELISTED
Akorn Inc
AKRX
$5.42M 0.2%
145,235
-704,247
-83% -$22M
PRGO icon
87
Perrigo
PRGO
$1.88B
$5.4M 0.2%
37,300
+18,400
+97% +$2.83M
HR
88
DELISTED
Healthcare Realty Trust Incorporated
HR
$5.3M 0.19%
187,224
– –
FOMX
89
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.29M 0.19%
652,145
+38,568
+6% +$288K
AGN.PRA
90
DELISTED
Allergan plc
AGN.PRA
$5.15M 0.19%
5,000
– –
THC icon
91
Tenet Healthcare
THC
$21.3B
$4.98M 0.18%
164,500
– –
RCKT icon
92
Rocket Pharmaceuticals
RCKT
$381M
$4.82M 0.17%
106,250
– –
MNK
93
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$4.62M 0.17%
61,900
-10,900
-15% -$734K
SGNT
94
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$4.56M 0.17%
286,650
-122,850
-30% -$1.93M
ORKA
95
Oruka Therapeutics
ORKA
$6.16B
$3.77M 0.14%
3,756
– –
ASRT
96
DELISTED
Assertio
ASRT
$3.63M 0.13%
3,333
– –
ADAP
97
DELISTED
Adaptimmune Therapeutics
ADAP
$3.58M 0.13%
296,934
+15,000
+5% +$147K
ADYX
98
DELISTED
Adynxx Inc
ADYX
$3.53M 0.13%
27,500
– –
HALO icon
99
Halozyme
HALO
$12.1B
$3.47M 0.13%
+200,000
New +$3.19M
BLUE
100
DELISTED
bluebird bio
BLUE
$3.17M 0.11%
3,809
-3,444
-47% -$3.44M
2 3
4
5 6

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Tekla Capital Management held 172 positions worth $2.76B, down 0.89% from $2.78B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Tekla Capital Management withdrew a net $144M in Q4 2015, closing 39 positions and reducing 25 holdings. Its most notable exit was Aetna Inc, an estimated $36.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Tekla Capital Management opened a new position in Sanofi worth $13M.

  • Tekla Capital Management's largest Q4 2015 buy was Sanofi: 305,000 shares worth $13M.
  • Tekla Capital Management added most to Allergan plc in Q4 2015, an estimated $27.4M increase.
  • Tekla Capital Management's biggest Q4 2015 reduction was Viatris, cutting an estimated $72.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2015, selling an estimated $36.3M.
  • Tekla Capital Management's ten largest holdings make up 48% of its $2.76B portfolio in Q4 2015.
  • Tekla Capital Management opened 14 new positions and closed 39 in Q4 2015.
  • Tekla Capital Management's portfolio value fell 0.89% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.